Abstract 4165
Background
Family caregivers (FCs) play important roles in the care provided to patients with incurable cancer. These patients experience a wide range of distressing symptoms. This symptom burden may add to the burden of FCs and consequently may have a negative impact on their quality of life (QoL). This study was conducted to determine the relationship between the symptom burden in a cohort of patients with incurable cancer and the QoL of their FCs.
Methods
The study included 94 dyads of hospitalized incurable cancer patients and one of their FCs. The symptom burden among patients was assessed using the revised Edmonton Symptom Assessment System (ESAS-r) and the QoL of their FCs was measured using the Medical Outcomes Study 36-Item Short-Form (MOS SF-36) questionnaire.
Results
Nausea was the most common symptom to associate with poorer QoL scores. There was a significant negative correlation between nausea and the following MOS SF-36 scales: physical functioning (r=-0.219, p = 0.034), role limitations due to physical health (r =-0.0228, p = 0.027), pain (r=-0.404, p < 0.001), general health (r =-0.222, p = 0.031) and health change (r=-0.317, p = 0.002). Other symptoms that correlated significantly with at least one of the MOS SF-36 scales were weakness, drowsiness, lack of appetite, shortness of breath, depression and wellbeing. The total ESAS-r score correlated significantly with poorer scores on the pain (r=-0.248, p = 0.016) and health change (r=-0.311, p = 0.002) scales of MOS SF-36. In addition; older FCs age, hours of care per day, total period of care, FCs employment and inadequate income correlated significantly with poorer scores of at least one of the MOS SF-36 scales.
Conclusions
The high symptom burden experienced by patients with incurable cancer may have a negative impact on the QoL of their FCs, especially the physical aspect.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Clinical Oncology Department, Menofia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3157 - Efficacy and safety of anlotinib in advanced leiomyosarcoma: Subgroup analysis of a phase IIB trial (ALTER0203)
Presenter: Yihebali Chi
Session: Poster Display session 1
Resources:
Abstract
3710 - The effect of treatment line on the efficacy of Anlotinib hydrochloride in advanced alveolar soft part sarcoma patients
Presenter: Zhiwei Fang
Session: Poster Display session 1
Resources:
Abstract
3184 - Prior exposure to pazopanib (PAZ) did not minor efficacy of regorafenib (REG) in non-adipocytic soft tissue sarcoma patients (pts)
Presenter: Nicolas Penel
Session: Poster Display session 1
Resources:
Abstract
798 - Pexidartinib (Pex) for locally advanced tenosynovial giant cell tumor (TGCT): characterization of hepatic adverse reactions (ARs)
Presenter: Sebastian Bauer
Session: Poster Display session 1
Resources:
Abstract
6117 - VEGFR2 and ITGA polymorphisms as novel pan-sarcoma biomarkers for sensitivity prediction as well as toxicity prevention anti-angiogenesis therapy in pediatric and young adult
Presenter: Qiyuan Bao
Session: Poster Display session 1
Resources:
Abstract
5450 - Reversion of resistance to mTOR inhibitors with the addition of exemestane in patients with malignant PEComa.
Presenter: Roberta Sanfilippo
Session: Poster Display session 1
Resources:
Abstract
4279 - Efficacy and Safety of VEGFR2 Inhibitor Apatinib combined with chemotherapy for Sarcoma in Stage IV
Presenter: Zhiwu Ren
Session: Poster Display session 1
Resources:
Abstract
5929 - Outcomes of metastatic soft tissue sarcoma treated with Pazopanib from dedicated medical oncology sarcoma clinic: A holistic care approach from a developing country
Presenter: Akhil Kapoor
Session: Poster Display session 1
Resources:
Abstract
2469 - Inhibition of mTOR signaling enhances Trabectedin activity in Soft Tissue Sarcoma
Presenter: David Moura
Session: Poster Display session 1
Resources:
Abstract
4210 - Efficacy and safety of apatinib for advanced gastrointestinal stromal tumors after failure of imatinib and sunitinib: An open-label, multicenter, single-arm, phase II trial
Presenter: Zhaolun Cai
Session: Poster Display session 1
Resources:
Abstract